1. Generics Bulletin
  2. >>Business
  3. >>Earnings

Fresenius Kabi’s EU Biosimilars ‘Lagging Behind Expectations’

COVID-19 Has Hit Impacted Market

 
• By Dean Rudge

Fresenius Kabi is looking to make headway into biosimilars but saw its progress limited by COVID-19 in Q2. Management gave an update on the company’s endeavors during the Q2 earnings call, including key tender victories.

Fresenius Kabi
Fresenius felt the impact of COVID-19 on its biosimilars business in Q2 • Source: Shutterstock

The shrinking market for the immunosuppressive adalimumab in the wake of COVID-19 led to Fresenius Kabi’s biosimilars business in Europe “lagging a bit behind our expectations” in the second quarter, even as the German firm scooped “fairly significant” tender wins in the UK and Italy for its Idacio (adalimumab) biosimilar.

Addressing investors as the Fresenius group of companies reported second-quarter results, Fresenius’ president, CEO and chairman, Stephan Sturm, emphasized the natural impact of COVID-19 on drugs that suppressed the immune system, in tandem with

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Earnings

More from Business

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.

Amneal Proud To Be ‘Made In America’ And Ready To Scale Up Its US Manufacturing

 
• By Urtė Fultinavičiūtė

Amneal has set itself apart from competitors who are scrambling to find alternatives if proposed US pharmaceutical tariffs come into place. For the New Jersey-based firm, this is an opportunity to embrace its American identity and open a new chapter of growth.

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.